Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D

← catalyst calendar

NCT07593625 · readout in 134 d

Sponsored by Insulet Corporation (industry) · PODD — their whole pipeline →.

Phase

Not applicable

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

80estimated

Sites

Country

New Zealand

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-05-25

actual

When the study began enrolling

Primary completion

2026-12-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-02-01

estimated

The whole study's end, after follow-up

First posted

2026-05-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Type 1 Diabetes
Type 1 Diabetes Mellitus
Diabetes (DM)

Interventions

Device: Omnipod M System
Device: Omnipod S

Primary outcomes

what the primary-completion date above is the date OF

Percentage of time <54 mg/dL

measured 72-hour Omnipod M Hotel Period

Percentage of time <70 mg/dL

measured 72-hour Omnipod M Hotel Period

Percentage of time >180 mg/dL

measured 72-hour Omnipod M Hotel Period

Percentage of time <54 mg/dL

measured 4-week Omnipod M outpatient

Percentage of time <54 mg/dL

measured Final 3 weeks of Omnipod S outpatient

Percentage of time <70 mg/dL

measured 4-week Omnipod M outpatient

Percentage of time <70 mg/dL

measured Final 3-weeks Omnipod S outpatient

Percentage of time >180 mg/dL

measured 4-week Omnipod M outpatient

Percentage of time >180 mg/dL

measured Final 3-weeks Omnipod S outpatient

Permalink · PODD's whole pipeline · Catalyst calendar · Every registered study · What changed